Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-17 of 17 for your search:
Drug:
pentostatin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POI-02818
, NIP-02-005, NCT00131313
2.
Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
3.
Phase I/II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone Hydrochloride in Patients With Previously Treated Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-05077
, MSKCC IRB PRotocol #05-077, NCT00546377
4.
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
OV06-001
, NCT00709215
5.
Phase I/II Study of T-Cell-Reduced Unrelated Donor Peripheral Blood Stem Cell Transplantation After Reduced-Intensity Conditioning Comprising Pentostatin and Low-Dose Total-Body Irradiation in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
19 to 75
Sponsor:
NCI
Protocol IDs:
UNMC-16407
, 164-07, NCT00816413
6.
Phase II Study of a Reduced-Intensity Preparative Regimen With Allogeneic Bone Marrow Transplantation in Patients With Myelodysplastic Syndromes
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
ECOG-E1902
, NCT00045305, E1902
7.
Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-2903
, NCT00074282, E2903
8.
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
0508000433
, NCT00402714
9.
Alemtuzumab and Pentostatin In T-Cell Neoplasms
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2004-0408
, NCT00453193
10.
Phase II Trial of Pentostatin and Targeted Busulfan
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
MCC15009
, NCT00496340
11.
Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab in Patients With Previously Untreated Intermediate- or High-Risk B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-05051
, MSKCC IRB 05-051, NCT00541034
12.
Phase II Study of Induction Therapy Comprising Rituximab, Pentostatin, and Cyclophosphamide Followed by Consolidation Therapy Comprising Lenalidomide in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
MAYO-MC0784
, MC0784, MAYO-07-002156, HOSPIRA-MC0784, NCT00602836
13.
Phase II Pilot Study of Low-Intensity Chemotherapy Comprising Pentostatin and Cyclophosphamide Followed By Allogeneic Hematopoietic Stem Cell Transplantation and Donor Th2 Cell Infusions in Patients With Metastatic Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0088
, 08-C-0088, 8242, NCI-P07312, NCT00641485
14.
Phase II Study of Pentostatin, Alemtuzumab, and Low-Dose Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-LS0881
, LS0881, NCT00669318
15.
Phase II Study of Pentostatin and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
UARIZ-05-0624-01
, 05-0624-01, HSC05110, UARIZ-SRC17920, NCT00698685
16.
GVH 0313: Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation
Phase:
Phase II
Type:
Supportive care
Status:
Active
Age:
Under 21
Sponsor:
Other
Protocol IDs:
045-2004
, NCT00228826
17.
Phase II Randomized Study of Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MCCRC-RC0783
, RC0783, MCCRC-08-002080, NCT00816595
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
